Lobbying registration dated 2026-03-31
Registrant: WILLIAM DEMPSTER
Client: AstraZeneca Canada
Targeted institutions:
Treasury Board Of Canada Secretariat (TBS)
Senate of Canada
Privy Council Office (PCO)
Global Affairs Canada (GAC)
House of Commons
Prime Minister's Office (PMO)
Health Canada (HC)
Public Health Agency of Canada (PHAC)
Indigenous Services Canada (ISC)
Patented Medicine Prices Review Board (PMPRB)
Finance Canada (FIN)
National Defence (DND)
Innovation, Science and Economic Development Canada (ISED)
Acts: Patent Act
Government funding received:
Lobbying activity details:
Engage with Canadian government officials to discuss and provide input on Canada's countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Scientific Research and Experimental Development
(SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Annual federal Budgets and Budget updates relating to the biopharmaceutical industry
Federally-funded public drug plans, including the Non-Insured Health Benefits Program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
Canada’s Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Establish accountability with Health Canada, Canada's Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
Public Health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
Engagement with the government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada